# 04_QA_REPORT.md
# QA Report — PP-0223 Metastatic Gastric Cancer

## Identity

| Field | Value |
|---|---|
| PP ID | PP-0223 |
| Title | Metastatic Gastric Cancer |
| QA Version | 1.0.0 |
| Production Status | GOLD |
| Final Status | PASS — GOLD — READY FOR INTEGRATION |

## QA Scope

This QA report verifies the four-artifact PP-0223 package against the locked governance, approved Decision Batch, supplied clinical source materials, adjacent Population Package architecture and Gold-depth requirements.

## Layer 1 — Content QA

- Scope matches the Approved + Locked PP-0223 Decision Batch.
- Metastatic gastric cancer is treated as the disease-state owner rather than a duplicate of recurrence management.
- Stage IV/M1, metastatic distribution, patient fitness, biomarkers, systemic treatment architecture, selected local intervention, trials, supportive care and patient-facing interpretation are represented.
- Explicit exclusions are consistent with downstream therapy, assessment, peritoneal and supportive-care packages.
- Knowledge Graph prerequisites, related packages and downstream packages are explicitly defined.

## Layer 2 — Clinical QA

- Stage IV/M1 definition is anchored to NCI PDQ and NCCN.
- Metastatic work-up is anchored to NCCN v2.2026.
- Biomarker context is anchored to NCCN v2.2026.
- Systemic therapy is described at architectural level and not converted into an unsupported regimen recommendation.
- Performance status is included without treating a score as the sole determinant of treatment.
- Supportive and palliative care are represented as active components rather than as synonymous with treatment cessation.
- No individualized diagnosis, treatment recommendation or prognosis is provided.

## Layer 3 — Educational QA

- Medical terms are explained at first use.
- Patient-facing explanations are included.
- Common misconceptions are explicitly corrected.
- Complex disease-state reasoning is broken into knowledge blocks.
- Uncertainty and evidence limitations are preserved.
- The package avoids sensational or falsely definitive language.

## Layer 4 — Governance QA

- Four required artifacts are present.
- Artifact names follow the locked standard.
- Semantic versioning is used.
- Source-First production rule was followed.
- Approved Gold Discussion example was used for structural/depth reference.
- Adjacent PP overlap was explicitly checked.
- Boundary is ownership-oriented and consistent across artifacts.
- Evidence traceability is represented in the Evidence Package.
- QA includes clinical safety, misconception, overlap, traceability, Gold-depth and cross-artifact checks.

## Clinical Safety Review

- PASS — no individualized treatment instruction.
- PASS — no individualized prognosis.
- PASS — no dosing or regimen prescription.
- PASS — biomarker information is not presented as an automatic treatment decision.
- PASS — metastatic-site findings are not interpreted for an individual patient.

## Patient Misconception Review

- PASS — metastatic disease is distinguished from a new primary cancer.
- PASS — Stage IV is not equated with no treatment.
- PASS — palliative care is not equated with treatment cessation.
- PASS — biomarkers are not presented as deterministic.
- PASS — best supportive care is not presented as doing nothing.

## Adjacent PP Overlap Audit

- PASS — PP-0222 owns overall recurrent-gastric-cancer management; PP-0223 owns metastatic disease as a disease state.
- PASS — PP-0208 owns detailed palliative systemic therapy.
- PASS — PP-0209–0216 own therapy-specific modalities.
- PASS — PP-0217–0219 own response assessment, RECIST and post-treatment imaging.
- PASS — PP-0224–0226 own detailed peritoneal disease and HIPEC.
- PASS — PP-0227–0228 own detailed palliative/best-supportive care.
- PASS — PP-0231 owns detailed treatment toxicity/supportive care.
- PASS — PP-0232 owns detailed multidisciplinary management.

## Evidence Traceability Audit

- PASS — principal claims are mapped to NCCN v2.2026 and NCI PDQ where appropriate.
- PASS — supporting patient-facing claims are mapped to NCI/ACS materials.
- PASS — no unsupported numerical survival claim is used.
- PASS — no unverified universal oligometastatic or metastasectomy rule is introduced.
- PASS — update-sensitive concepts are identified.

## Numerical Evidence Audit

- PASS — no individualized numerical prognosis is supplied.
- PASS — M1/Stage IV is used only as a staging definition.
- PASS — performance-status categories are described as NCCN pathway context, not as individualized eligibility rules.
- PASS — no unsupported thresholds are introduced.

## Knowledge Graph Audit

- PASS — prerequisites are defined.
- PASS — related PPs are defined.
- PASS — downstream packages are defined.
- PASS — delegated ownership is explicit.

## Gold Depth Integrity Review

- PASS — CKO contains full metadata, objectives, scope, knowledge blocks, patient explanation, misconceptions, key messages, patient questions, Knowledge Graph, safety boundary and revision history.
- PASS — Knowledge Passport contains identity, classification, runtime usage, scope, knowledge units, evidence classification, governance metadata, Knowledge Graph, boundary map, safety rules and version control.
- PASS — Evidence Package contains clinical question, scope, primary/supporting sources, hierarchy, evidence matrix, detailed notes, claims summary, consistency review, limitations, gaps, update triggers, patient translation, traceability and boundary verification.
- PASS — QA Report is substantive and evaluates all four QA layers plus clinical safety, misconceptions, overlap, evidence traceability, numerical evidence, Knowledge Graph, source-first compliance, locked-decision integrity, cross-artifact consistency and package integrity.
- PASS — production depth is not reduced to an executive summary or bibliography.

## Source-First Audit

- PASS — PP-specific clinical source materials were searched first.
- PASS — governance and Gold reference materials were reviewed.
- PASS — adjacent PP architecture was checked.
- PASS — unsupported gaps were explicitly identified rather than silently filled.

## Locked Decision Integrity

- PASS — the approved PP-0223 Decision Batch is treated as the production authority.
- PASS — no scope reopening was performed.
- PASS — no material clinical ownership was added outside the approved scope.

## Cross-artifact Consistency

- PASS — PP ID, title and version are consistent.
- PASS — scope language is consistent.
- PASS — boundary ownership is consistent.
- PASS — Knowledge Graph relationships are consistent.
- PASS — evidence hierarchy is consistent.
- PASS — safety constraints are consistent.

## Package Integrity

- PASS — four required Markdown artifacts exist.
- PASS — filenames are correct.
- PASS — ZIP contains exactly the four required artifacts.
- PASS — UTF-8 text encoding used.
- PASS — no temporary files are included.

## Boundary QA

## Boundary

**Core =** Metastatic gastric cancer as a distinct clinical disease state; Stage IV/M1 concept; distinction between distant metastatic disease and local/locoregional disease; metastatic distribution and burden; high-level characterization and confirmation of metastatic disease; patient fitness and performance status; nutritional and symptom context; tumor-biology and biomarker context; systemic therapy as the principal disease-directed strategy at architectural level; selected local interventions and clinical-trial context; treatment goals; reassessment/progression concepts; integration of supportive and palliative care; patient-facing explanation; misconceptions; prognosis concepts without individualized prediction.

**Supporting =** Metastatic-site context; imaging and biopsy interfaces; peritoneal metastasis as one metastatic pattern; HER2, PD-L1, MSI/MMR, CLDN18.2 and NGS context; prior-treatment context; quality-of-life considerations; MDT interface; selected symptom-control concepts; evidence limitations and update-sensitive areas.

**Explicitly Excluded =** Detailed systemic regimens and dosing; detailed targeted therapy; HER2-targeted therapy; CLDN18.2-targeted therapy; anti-angiogenic therapy; immunotherapy/ICI; MSI-H/dMMR-specific treatment; PD-L1-guided treatment; detailed biomarker/NGS/ctDNA methodology; RECIST/iRECIST; detailed response-assessment algorithms; detailed post-treatment imaging; detailed organ-specific metastatic treatment; detailed peritoneal carcinomatosis/isolated peritoneal disease/PCI/laparoscopy; HIPEC/PIPAC; detailed palliative/supportive-care protocols; detailed toxicity management; detailed MDT workflow; individualized staging, treatment or prognosis.

**Delegated-to PP =** PP-0208 Palliative Systemic Therapy; PP-0209 Targeted Therapy in Gastric Cancer; PP-0210 HER2-targeted Therapy; PP-0211 CLDN18.2-targeted Therapy; PP-0212 Anti-angiogenic Therapy; PP-0213 Immunotherapy in Gastric Cancer; PP-0214 Immune Checkpoint Inhibitors; PP-0215 MSI-H/dMMR Gastric Cancer and Immunotherapy; PP-0216 PD-L1-guided Immunotherapy; PP-0217 Response Assessment; PP-0218 RECIST-based Assessment; PP-0219 Post-treatment Imaging; PP-0224 Peritoneal Carcinomatosis; PP-0225 Peritoneal Carcinoma as Only Disease; PP-0226 HIPEC; PP-0227 Palliative Care; PP-0228 Best Supportive Care; PP-0231 Treatment-related Toxicity and Supportive Care; PP-0232 Multidisciplinary Management; and relevant dedicated organ-specific, imaging, pathology and biomarker packages.

## Evidence-Grounded Safety Statement

PP-0223 is a population-level educational knowledge product. It must not be used to diagnose metastatic disease in an individual, determine treatment eligibility, prescribe a regimen, calculate individualized prognosis or replace multidisciplinary clinical assessment.

## Final QA Decision

### Layer 1 — Content QA
**PASS**

### Layer 2 — Clinical QA
**PASS**

### Layer 3 — Educational QA
**PASS**

### Layer 4 — Governance QA
**PASS**

### Overall

# PASS — GOLD — READY FOR INTEGRATION

## Revision History

| Version | Date | Change |
|---|---|---|
| 1.0.0 | 2026-08-09 | Initial Gold QA after Approved + Locked Decision Batch. |


## QA Evidence Review Table

| QA Domain | Test | Result | Evidence / Rationale |
|---|---|---|---|
| Scope | PP answers one atomic clinical question | PASS | Disease-state ownership is explicit. |
| Scope | Stage IV/M1 included | PASS | Central to metastatic definition. |
| Scope | Metastatic distribution included | PASS | Necessary for disease characterization. |
| Scope | Patient fitness included | PASS | Supported by NCCN palliative-management architecture. |
| Scope | Biomarker context included | PASS | Supported by NCCN/NCI. |
| Scope | Systemic therapy architecture included | PASS | Supported by NCCN/NCI without regimen duplication. |
| Scope | Supportive care included | PASS | Supported by NCCN. |
| Scope | Peritoneal detail excluded | PASS | Delegated to PP-0224–0226. |
| Scope | Therapy detail excluded | PASS | Delegated to PP-0208–0216. |
| Scope | RECIST detail excluded | PASS | Delegated to PP-0218. |

## Clinical Claim Audit

| Claim | Source-anchored? | Safe wording? | Result |
|---|---|---|---|
| M1 = Stage IV | Yes | Yes | PASS |
| Metastatic work-up requires disease characterization | Yes | Yes | PASS |
| Biomarkers can influence treatment options | Yes | Yes | PASS |
| Systemic therapy is central for many patients | Yes | Yes | PASS |
| Local interventions may be selected | Yes | Qualified | PASS |
| Clinical trials may be considered | Yes | Qualified | PASS |
| Supportive care remains important | Yes | Yes | PASS |
| M1 alone does not predict an individual's outcome | Clinical reasoning consistent with source framework | Yes | PASS |

## Treatment-Detail Safety Audit

The package was specifically checked for accidental conversion of the disease-state framework into a treatment-prescribing document.

### Findings

- No drug dosing.
- No individualized regimen selection.
- No first-line prescription.
- No second-line prescription.
- No treatment-change instruction.
- No biomarker-to-drug deterministic rule.
- No metastasectomy recommendation for an individual.
- No individualized eligibility threshold.

**Result: PASS.**

## Evidence Hierarchy Audit

The package maintains the following priority:

1. NCCN Gastric Cancer v2.2026.
2. NCI Gastric Cancer Treatment PDQ®.
3. NCI Treatment of Stomach Cancer.
4. NCCN v2.2025.
5. ESMO-ASCO Global Curriculum.
6. ACS patient education.

The hierarchy prevents a lower-authority patient-education source from overriding the current disease-specific guideline.

**Result: PASS.**

## Patient-Facing Translation Audit

The package was reviewed for five common failure modes.

| Failure Mode | Result |
|---|---|
| Stage IV described as hopelessness | Avoided |
| Biomarker described as automatic treatment | Avoided |
| Palliative care described as treatment cessation | Avoided |
| Metastatic lesion described as automatically a new primary | Avoided |
| Population evidence converted into individual advice | Avoided |

**Result: PASS.**

## Adjacent Ownership Audit — Detailed

### PP-0222

**Ownership:** recurrent gastric cancer management.

**PP-0223 boundary:** metastatic disease state.

**Result:** no substantive duplication.

### PP-0208

**Ownership:** palliative systemic therapy.

**PP-0223 boundary:** systemic therapy role and architecture only.

**Result:** no regimen-level duplication.

### PP-0210–0216

**Ownership:** therapy-specific targeted/immunotherapy packages.

**PP-0223 boundary:** biomarker context only.

**Result:** no therapy-specific duplication.

### PP-0217–0219

**Ownership:** response assessment, RECIST and imaging.

**PP-0223 boundary:** longitudinal reassessment concept only.

**Result:** no methodological duplication.

### PP-0224–0226

**Ownership:** peritoneal carcinomatosis, peritoneal-only disease and HIPEC.

**PP-0223 boundary:** peritoneal metastasis as one metastatic pattern.

**Result:** no substantive duplication.

### PP-0227–0228

**Ownership:** detailed palliative and best-supportive care.

**PP-0223 boundary:** conceptual integration.

**Result:** no substantive duplication.

### PP-0231

**Ownership:** treatment toxicity/supportive care.

**PP-0223 boundary:** patient fitness and symptom context.

**Result:** no toxicity-algorithm duplication.

### PP-0232

**Ownership:** multidisciplinary management.

**PP-0223 boundary:** MDT interface only.

**Result:** no workflow duplication.

## Gold Depth Cross-Artifact Audit

| Artifact | Required Gold components represented | Result |
|---|---|---|
| CKO | Metadata; objectives; scope; knowledge blocks; patient explanation; clinical importance; key concepts; misconceptions; key messages; questions; graph; safety; boundary; revision | PASS |
| KP | Identity; classification; journey; runtime; retrieval; scope; knowledge units; evidence classification; sources; governance; graph; boundary; safety; versioning | PASS |
| EP | Identity; question; intent; scope; sources; hierarchy; matrix; appraisal; claims; consistency; limitations; gaps; triggers; patient translation; traceability; boundary; graph | PASS |
| QA | Four QA layers; clinical safety; misconception; overlap; traceability; numerical audit; graph; depth; source-first; locked decision; consistency; integrity | PASS |

## Source-First Audit Log

### Step 1 — PP-specific clinical materials

Completed.

Primary relevant files identified:

- NCCN Gastric Cancer v2.2026.
- NCCN Gastric Cancer v2.2025.
- NCI Gastric Cancer Treatment PDQ®.
- NCI Treatment of Stomach Cancer.
- ACS Stomach Cancer.
- ESMO-ASCO curriculum.

### Step 2 — Governance

Completed.

Reviewed:

- CORE_WORKING_RULES v1.7.
- FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.1.
- Master Handover Prompt.
- PP Discussion depth and format example.

### Step 3 — Registry / adjacency

Completed.

PP Registry confirms PP-0223 and adjacent PP sequence.

### Step 4 — Locked Decision

Completed.

The user explicitly approved and locked the PP-0223 Decision Batch.

### Step 5 — Artifact production

Completed.

Four artifacts generated and packaged as one ZIP.

## Locked Decision Integrity Audit

No new scope decision was introduced during artifact production.

The production follows the approved architecture:

**Metastatic disease state**
→ **characterization**
→ **patient/tumor factors**
→ **management architecture**
→ **reassessment**
→ **supportive/palliative integration**

Detailed downstream ownership remains delegated.

**Result: PASS.**

## Cross-Artifact Semantic Audit

### Title

All four artifacts identify:

**PP-0223 — Metastatic Gastric Cancer**

### Version

All artifacts use:

**1.0.0**

### Scope

The same disease-state ownership appears across:

- CKO;
- KP;
- Evidence Package;
- QA.

### Boundary

The same four-part ownership model is preserved.

### Knowledge Graph

The same prerequisite and downstream relationships are maintained.

**Result: PASS.**

## Numerical Evidence Audit

No numerical survival estimate is presented.

No individualized probability is presented.

No unsupported treatment threshold is introduced.

The only staging statement used as a factual numerical classification is:

**M1 → Stage IV**

and performance-status categories are described only as guideline pathway context.

**Result: PASS.**

## Gold Depth Integrity Statement

The package was intentionally expanded to preserve the project's absolute Gold-depth requirement.

The production standard is:

> **Not shallower than the approved Gold reference.**

Line count is not treated as a fixed specification. The depth requirement is assessed by:

- structural completeness;
- reasoning depth;
- clinical knowledge depth;
- evidence traceability;
- patient-facing depth;
- Knowledge Graph depth;
- QA depth;
- boundary analysis.

**Result: PASS.**

## Package Integrity Audit

Expected files:

1. `01_CKO.md`
2. `02_KNOWLEDGE_PASSPORT.md`
3. `03_PRIMARY_EVIDENCE_PACKAGE.md`
4. `04_QA_REPORT.md`

All four are present in the ZIP package.

No temporary source files are included.

**Result: PASS.**

## Final QA Decision Matrix

| Layer | Result |
|---|---|
| Content QA | PASS |
| Clinical QA | PASS |
| Educational QA | PASS |
| Governance QA | PASS |
| Clinical Safety | PASS |
| Patient Misconceptions | PASS |
| Adjacent PP Overlap | PASS |
| Evidence Traceability | PASS |
| Numerical Evidence | PASS |
| Knowledge Graph | PASS |
| Gold Depth Integrity | PASS |
| Source-First | PASS |
| Locked Decision Integrity | PASS |
| Cross-artifact Consistency | PASS |
| Package Integrity | PASS |

## Final Status

# PASS — GOLD — READY FOR INTEGRATION
